Memorial Sloan Kettering pediatric oncologist Julia Glade Bender

Julia Glade Bender, MD

Pediatric Hematologist-Oncologist

My Role at MSK

Areas of Expertise

Conditions I Treat

Pediatric cancers
Pediatric sarcomas
Neuroblastoma

My Specialties

Pediatric cancer care
Clinical trials
Early-phase clinical trials

View all

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

English

About Me

What I Do at MSK

Vice Chair for Clinical Research

Get To Know Me

I am a pediatric oncologist who specializes in caring for young people with solid tumors of the bone and soft tissues, including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, germ cell tumors, and other rare tumors. As cliché as it might sound, I love talking to kids of all ages, right up through young adulthood. With five kids of my own, I’ve had a lot of practice. As a member of the MSK Kids team, I am honored to guide patients and their families through what is likely to be one of the most difficult experiences of their lives. There is no greater satisfaction than delivering children, teens, and young adults back to the lives they were meant to lead and allowing them to become the people they were destined to be.

To provide the best treatment available and build the most effective team for a child, I strive to understand each person as an individual. How families communicate, how people cope, and what they need also come into play. With 80 percent of pediatric cancer patients surviving, the context of cancer care during developmental stages can have a profound impact. Kids still need to play like kids. These young patients struggle with independence, relationships, body image, and visions for the future. At MSK Kids, we help them navigate these issues as well as our complex healthcare system.

At the same time, I respect and admire scientific discovery. There’s a lot about tumor biology that can be translated into better therapies for children. We need to understand what makes an individual tumor tick and shut it down. For many people, standard chemotherapy using existing anticancer drugs will continue to be the best approach. But for others, there’s great hope that newer technologies will result in better biologic and targeted therapies. These advances can take advantage of the differences between tumor cells and normal cells. At MSK Kids, we analyze the genetics of every child’s tumor using a test called MSK-IMPACT™. This testing allows us to quickly identify whether there are newer drugs that can be added to or replace standard therapies.

My research occurs by the bedside and in the clinic, in the form of clinical trials. I help develop and lead national first-in-child studies. I feel strongly that children should have access to new drugs in their earliest stages of testing, especially if a drug has been developed to target specific molecules driving the growth of their tumors. At MSK, we have broad expertise and collaborate with our colleagues caring for adults to offer the newest therapies to children sooner, including those that help or train the body’s immune system to recognize cancer. We try our best to learn from every patient and share that knowledge with one another, never losing sight that each patient is an individual. What is good for one may not be the best choice for another.

My overarching goal is to apply my research and patient care experience to improve the care of all young people with cancer. I hope that in the future, we will have more-effective therapies with fewer side effects. With my incredible colleagues, I put my heart and mind to work each day for the kids we are honored to care for. I aim to cure cancer one patient at a time, and I’m not going to stop until we get there.

My Role at MSK

A pediatric hematologist-oncologist is a doctor who treats cancers and blood diseases in children, adolescents and young adults.

Conditions I Treat

Pediatric cancers
Pediatric sarcomas
Neuroblastoma
Germ cell tumors
Osteosarcoma
Pediatric Ewing sarcoma
Pediatric rhabdomyosarcomas

My Specialties

Pediatric cancer care
Clinical trials
Early-phase clinical trials
Precision medicine
Adolescent and young adult (AYA) cancer care
Chemotherapy

Education

MD, University of Pennsylvania School of Medicine

Residencies

General Pediatrics – Mount Sinai Medical Center

Awards and Honors

Castle Connolly: Exceptional Women in Medicine (2024)
Castle Connolly: America’s Top Doctor (2024)
Top Doctors New York Metro Area, Castle Connolly (2023)
Exceptional Women in Medicine Award, Castle Connolly (2023)
Castle Connolly: America's Top Doctors (2023)
Castle Connolly: New York Magazine Top Doctors (2014, 2016-2020)

Fellowships

Pediatric Hematology/Oncology – Memorial Sloan Kettering Cancer Center

Board Certifications

Pediatric Hematology-Oncology
Pediatrics

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Make an appointment

Aetna Medicare Advantage (MTA and NYC retirees only)

In Network Coverage Type
PPO

Make an appointment

Anthem BCBS and other BCBS licensee plans

In Network Coverage Type
PPO, POS, EPO, HMO

See updates

Make an appointment

Anthem BCBS Health Plus

In Network Coverage Type
HMO

See updates

Make an appointment

Anthem Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

See updates

Make an appointment

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

See updates

Make an appointment

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

See updates

Make an appointment

Carrum Health

In Network Coverage Type
Supplemental

Make an appointment

Cigna

In Network Coverage Type
PPO, POS, HMO

Make an appointment

Connecticare

In Network Coverage Type
POS, EPO, HMO

Make an appointment

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Make an appointment

Emblem Essential

In Network Coverage Type
HMO

Make an appointment

Emblem Medicare Advantage (Medicare Choice PPO Network and VIP Prime Network Only)

In Network Coverage Type
PPO, HMO

Make an appointment

Empire Essential

In Network Coverage Type
HMO

Make an appointment

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

See updates

Make an appointment

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Make an appointment

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Make an appointment

Fidelis Medicare Advantage

In Network Coverage Type
HMO

Make an appointment

First Health

In Network Coverage Type
PPO

Make an appointment

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Make an appointment

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Make an appointment

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Make an appointment

Healthsmart

In Network Coverage Type
PPO EPO

Make an appointment

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

See updates

Make an appointment

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

See updates

Make an appointment

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

See updates

Make an appointment

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

See updates

Make an appointment

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Make an appointment

Husky CT Medicaid

In Network Coverage Type
State Government

Make an appointment

Magnacare

In Network Coverage Type
PPO, POS, EPO

Make an appointment

Straight NJ Medicaid

In Network Coverage Type
State Government

Make an appointment

Straight NY Medicaid

In Network Coverage Type
State Government

Make an appointment

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Make an appointment

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

Make an appointment

MVP

In Network Coverage Type
PPO/OAP

Make an appointment

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

Make an appointment

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Make an appointment

Oscar

In Network Coverage Type
HMO/EPO

Make an appointment

Oxford

In Network Coverage Type
PPO, EPO

Make an appointment

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Make an appointment

Qualcare

In Network Coverage Type
PPO, POS, HMO

Make an appointment

Tricare

In Network Coverage Type
PPO, HMO

Make an appointment

UMR

In Network Coverage Type
PPO, POS

Make an appointment

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Make an appointment

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

New Patients

Scheduling an appointment is easy. Click or call 833-MSK-KIDS— we’re available 24 hours a day, 7 days a week

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Glade Bender sees patients at one location.

Office Phone

212-639-6729

Location

New York, NY

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Pediatrics doctors

Clinical Trials

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.

Oberg JA, Ruiz J, Ali‐Shaw T, Schlechtweg KA, Ricci A, Kung AL, Chung WK, Appelbaum PS, Glade Bender JL, Levine JM. Whole‐Genome and Whole‐Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations, JCO Precision Oncology. 2018 :2, 1-11.

Oberg JA*, Glade Bender JL*, Sulis ML*, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Medicine. Genome Medicine. Dec 23, 2016; 8(1):133. DOI: 10.1186/s13073-016-0389-6. [PMID: 28007021] *Contributed equally

Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print].

Tannenbaum-Dvir S, Glade-Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene 1 EML4-NTRK3 in an aggressive case of congenital fibrosarcoma. Cold Spring Harbor Molecular Case Studies. 2015: a000471.

Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children’s oncology group phase I consortium. Pediatr Blood Cancer. Pediatr Blood Cancer. 2015 Jan;62(1):45-51. [Epub 2014 Sep 24; PMID:25257751].

Glade Bender J, Lee A, Reid JM, Baruchel S, Roberts T, Voss S, Wu B, Ahern C, Ingle AM, Harris P, Weigel B, Blaney SM. A Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children with Refractory Solid Tumors including Soft Tissue Sarcoma: A Children’s Oncology Group Phase I Consortium Report. J Clin Oncol. 2013 Aug 20;31(24):3034-3043. [Epub 2013 Jul 15; PMID: 23857966].

Glade Bender J, Blaney SM, Borinstein SC, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR. A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report. Clin Cancer Res. 2012 Sep 15;18(18):5081-9. [PMID: 22791883].

Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405[PMID: 18202416].

Publications on PubMed

Visit PubMed for a full listing of Dr. Glade Bender’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Julia Glade Bender discloses the following relationships and financial interests:

Alex's Lemonade Stand Foundation
Professional Services and Activities
Columbia University
Intellectual Property Rights
Eisai
Professional Services and Activities
European Science Foundation
Professional Services and Activities
Jazz Pharmaceuticals
Professional Services and Activities (Uncompensated)
Jed Ian Taxel Foundation for Rare Cancer Research
Professional Services and Activities (Uncompensated)

Merck Sharp & Dohme
Professional Services and Activities (Uncompensated)
Neuroblastoma UK
Professional Services and Activities
Pfizer, Inc.
Professional Services and Activities (Uncompensated)
Solving Kids' Cancer UK
Professional Services and Activities (Uncompensated)
Springworks Therapeutics
Professional Services and Activities (Uncompensated)
St. Baldrick's Foundation
Fiduciary Role / Position; Professional Services and Activities (Uncompensated)

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures